Glenmark Pharmaceuticals Limited Earnings Summary — Q4 FY2026
Glenmark Pharmaceuticals Reports Muted Sequential Growth in Q4 FY26 Amid Substantial Debt Reduction
Key Takeaways
- Revenue for Q4 FY26 grew 15.8% year-on-year to ₹3,771 Cr, though it declined slightly on a sequential basis.
- The company achieved a massive recovery in Net Profit compared to the nominal ₹4 Cr recorded in the same quarter last year.
- Operating Profit Margin improved to 20% from 17% YoY, despite a cooling off from the exceptional 39% seen in Sep 2025.
- Debt levels have been drastically reduced, with total borrowings falling from ₹2,473 Cr in Mar 2025 to just ₹594 Cr in Mar 2026.
- Working capital remains a significant drag, with inventory levels rising to ₹4,390 Cr by fiscal year-end.
- The tax rate stabilized at 22% for the quarter, a significant normalization compared to the high volatility seen in previous years.
- Other income remained negative at -₹184 Cr, impacting the final bottom line performance for the quarter.
Management Guidance
Management is focused on pivoting toward specialty dermatology and respiratory products to move up the value chain. Strategic efforts are underway to contain costs and improve the working capital cycle, which currently exceeds the industry median.
Sentiment Shift
Improving
Outlook
The outlook remains positive regarding solvency due to near debt-free status, but operational volatility in the US generics market and high inventory levels present near-term hurdles for PAT stability.
← Back to Glenmark Pharmaceuticals Limited AI analysis
Unlock the full report
Deep-dive sections, financial charts, AI chat and PDF export are available with Premium.
This summary is AI-generated from Glenmark Pharmaceuticals Limited's latest annual report and public disclosures. It is for informational purposes only and is not investment advice.